Literature DB >> 31301334

The path from scientific discovery to cures for epilepsy.

Gemma L Carvill1, Chris G Dulla2, Dan H Lowenstein3, Amy R Brooks-Kayal4.   

Abstract

The epilepsies are a complex group of disorders that can be caused by a myriad of genetic and acquired factors. As such, identifying interventions that will prevent development of epilepsy, as well as cure the disorder once established, will require a multifaceted approach. Here we discuss the progress in scientific discovery propelling us towards this goal, including identification of genetic risk factors and big data approaches that integrate clinical and molecular 'omics' datasets to identify common pathophysiological signatures and biomarkers. We discuss the many animal and cellular models of epilepsy, what they have taught us about pathophysiology, and the cutting edge cellular, optogenetic, chemogenetic and anti-seizure drug screening approaches that are being used to find new cures in these models. Finally, we reflect on the work that still needs to be done towards identify at-risk individuals early, targeting and stopping epileptogenesis, and optimizing promising treatment approaches. Ultimately, developing and implementing cures for epilepsy will require a coordinated and immense effort from clinicians and basic scientists, as well as industry, and should always be guided by the needs of individuals affected by epilepsy and their families. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal model; Big data; Biomarker; Cellular model; Cure; Drug-screening; Epigenetics; Epilepsy; Epileptogenesis; Genetics; Optogenetics

Mesh:

Substances:

Year:  2019        PMID: 31301334     DOI: 10.1016/j.neuropharm.2019.107702

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects.

Authors:  Marwa M Nagib; Sicheng Zhang; Nelufar Yasmen; Lexiao Li; Ruida Hou; Ying Yu; Vijay K Boda; Zhongzhi Wu; Wei Li; Jianxiong Jiang
Journal:  Epilepsia       Date:  2022-02-18       Impact factor: 5.864

Review 2.  TRPC channels as emerging targets for seizure disorders.

Authors:  Ying Yu; Wei Li; Jianxiong Jiang
Journal:  Trends Pharmacol Sci       Date:  2022-07-12       Impact factor: 17.638

Review 3.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

4.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

Review 5.  Liquid biopsies in epilepsy: biomarkers for etiology, diagnosis, prognosis, and therapeutics.

Authors:  Jordan H Whitlock; Tabea M Soelter; Avery S Williams; Andrew A Hardigan; Brittany N Lasseigne
Journal:  Hum Cell       Date:  2021-10-25       Impact factor: 4.174

Review 6.  The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.

Authors:  Wolfgang Löscher; Pavel Klein
Journal:  CNS Drugs       Date:  2021-06-18       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.